Cyclacel Pharmaceuticals (NASDAQ:CYCC) Earns Sell Rating from Analysts at StockNews.com

StockNews.com assumed coverage on shares of Cyclacel Pharmaceuticals (NASDAQ:CYCC) in a report published on Tuesday. The brokerage issued a sell rating on the biotechnology company’s stock.

Separately, Roth Capital lowered Cyclacel Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, October 23rd.

Cyclacel Pharmaceuticals Price Performance

NASDAQ CYCC opened at $0.33 on Tuesday. The company has a market cap of $2.08 million, a P/E ratio of -0.04 and a beta of 0.38. Cyclacel Pharmaceuticals has a 12 month low of $0.32 and a 12 month high of $4.00. The company has a 50-day moving average of $0.56 and a 200-day moving average of $1.11.

Cyclacel Pharmaceuticals (NASDAQ:CYCC) last issued its quarterly earnings results on Tuesday, November 12th. The biotechnology company reported ($0.18) EPS for the quarter, topping the consensus estimate of ($0.54) by $0.36. The firm had revenue of $0.01 million during the quarter, compared to analyst estimates of $0.01 million. Cyclacel Pharmaceuticals had a negative net margin of 18,150.00% and a negative return on equity of 1,901.11%. As a group, equities research analysts anticipate that Cyclacel Pharmaceuticals will post -1.95 EPS for the current year.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in Cyclacel Pharmaceuticals stock. Armistice Capital LLC acquired a new position in Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC) in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 134,000 shares of the biotechnology company’s stock, valued at approximately $217,000. Armistice Capital LLC owned approximately 9.18% of Cyclacel Pharmaceuticals as of its most recent SEC filing. Institutional investors and hedge funds own 23.58% of the company’s stock.

Cyclacel Pharmaceuticals Company Profile

Cyclacel Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer and other proliferative diseases in the United States, the United Kingdom, and internationally. The company's lead product includes fadraciclib, a cyclin dependent kinase Inhibitors (CDK) that is in Phase 1/2 clinical trial for the treatment of solid tumors and hematological malignancies, as well as in combination with venetoclax to treat relapsed or refractory chronic lymphocytic leukemia; and Plogosertib, a polo-like kinase inhibitor program, which is in Phase 1/2 clinical trial for the treatment of advanced solid tumors and hematological malignancies.